Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:47:15 EDT Wed 08 May 2024
Enter Symbol
or Name
USA
CA



Q:GERN - GERON CORP - http://www.geron.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GERN - Q0.23.81·3.9020.03.81-0.06-1.68,898.632,86715,0253.845  3.90  3.7754.30  1.6416:23:50May 0215 min RT 2¢

Recent Trades - Last 10 of 15025
Time ETExPriceChangeVolume
16:23:50Q3.83-0.04100
16:16:38Q3.84-0.0322
16:15:18Q3.81-0.067,417
16:11:17Q3.82-0.05100
16:06:21Q3.80-0.07100
16:02:07Q3.81-0.06500,000
16:02:04Q3.81-0.06179
16:02:00Q3.81-0.0610,256
16:01:53Q3.81-0.0631,081
16:01:45Q3.81-0.06117

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-02 07:00U:GERNNews ReleaseGeron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
2024-04-25 16:30U:GERNNews ReleaseGeron to Announce First Quarter 2024 Financial Results on May 2, 2024
2024-04-18 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-03 16:30U:GERNNews ReleaseGeron to Participate at Upcoming Investor Conferences in April
2024-03-19 09:07U:GERNNews ReleaseGeron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2024-03-14 15:54U:GERNNews ReleaseGeron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
2024-02-28 07:05U:GERNNews ReleaseGeron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
2024-02-22 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-14 16:30U:GERNNews ReleaseGeron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
2024-01-18 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-12 08:30U:GERNNews ReleaseGeron to Participate in the B. Riley Securities Virtual Oncology Conference
2023-12-21 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-11 16:15U:GERNNews ReleaseGeron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
2023-12-06 08:00U:GERNNews ReleaseGeron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
2023-12-04 05:00U:GERNNews ReleaseGeron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
2023-11-28 08:00U:GERNNews ReleaseGeron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
2023-11-16 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-07 16:30U:GERNNews ReleaseGeron to Participate at Upcoming Investor Conferences in November
2023-11-02 09:00U:GERNNews ReleaseGeron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
2023-11-02 08:00U:GERNNews ReleaseGeron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results